Redeye welcomes the resumed FDA review of AroCell's 510(k) application – an anticipated event where the FDA's final decision should be announced within the coming 90 days. An eventual approval would be significant for the company and an important step towards its ambitions. The share is currently stretching beyond our Base Case of SEK 5 after a hastily upwards momentum. However, a timeline of 90 days until eventual approval could sustain momentum but a cooldown, too, is likely, we judge.

info@redeye.se (Redeye.se)

Redeye AB - Redeye.se